Abramson JS, Palomba ML, Gordon LI, et al. Pivotal safety and efficacy results from TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphomas. Presented at: 61st American Society of Hematology Annual Meeting and Exposition; December 7-10, 2019; Orlando, FL. Abstract 241.
Abramson JS. Anti-CD19 CAR T-cell therapy for B-cell non-Hodgkin lymphoma. Transfus Med Rev. 2020;34:29-33.
Batlevi CL, Matsuki E, Brentjens RJ, Younes A. Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol. 2016;13:25-40.
Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800-1808.
Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498-505.
Hucks G, Rheingold SR. The journey to CAR T cell therapy: the pediatric and young adult experience with relapsed or refractory B-ALL. Blood Cancer J. 2019;9:10.
Jacobson CA, Chavez JC, Seghal AR, et al. Interim analysis of ZUMA-5: a phase II study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. 2020 ASCO Virtual Program; May 29-31, 2020. Abstract 8008. doi: 10.1200/JCO.2020.38.15_suppl.8008
Kuhnl A, Roddie C, Tholouli E, et al. Outcome of high-grade lymphoma patients treated with CD19 CAR-T – updated real-world experience in the UK. Presented at: 25th European Hematology Association Annual Congress; June 11-21, 2020. Abstract S243.
Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol. 2019;20:31-42.
Ortiz-Maldonado V, Rives S, Alonso-Saladrigues A, et al. CART19-BE-01: a European academic trial on the administration of ARI-0001 cells in patients with acute lymphoblastic leukemia and other CD19+ lymphoproliferative disorders. Presented at: 25th European Hematology Association Annual Congress; June 11-21, 2020. Abstract S288.
Osborne W, Marzolini M, Tholouli E, et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with relapsed/refractory DLBCL. 2020 ASCO Virtual Program; May 29-31, 2020. Abstract 8001. doi: 10.1200/JCO.2020.38.15_suppl.8001
Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45-56.
Siddiqi T, Dorritie KA, Soumerai JD, et al. TRANSCEND CLL 004: Minimal residual disease negative responses after lisocabtagene maraleucel, a CD19-directed CAR T cell product, in patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Presented at: 2019 ASCO Annual Meeting; May 31 – June 4, 2019; Chicago, IL. Abstract 7501.
Wang M, Rossi JM, Munoz J, et al. Product characteristics and pharmacological profile of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in the phase II registrational ZUMA-2 trial. 2020 ASCO Virtual Program; May 29-31, 2020. Abstract 8008. doi: 10.1200/JCO.2020.38.15_suppl.3023

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.

Faculty

Jeremy Abramson, MD

Associate Professor of Medicine
Harvard Medical School
Director
Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts, United States

Disclosures

Disclosure: Jeremy Abramson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allogene; Abbvie; Bristol Myers Squibb; Celgene; EMD Serono; Karyopharm; Kite Pharma; Morphosys; Novartis; Roche
Received grants for clinical research from: Celgene; Seattle Genetics

Umberto Vitolo, MD

Hematology Consultant
Candiolo Cancer Institute
Candiolo, Italy

Disclosures

Disclosure: Umberto Vitolo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene; Gilead; Janssen; Novartis
Served as a speaker or a member of a speakers bureau for: AbbVie; Celgene; Gilead; Janssen; Roche

Marie José Kersten, MD, PhD

Professor of Hematology
Department of Hematology
LYMMCARE (Lymphoma and Melanoma Center Amsterdam) Institute
Amsterdam University Medical Centers
Amsterdam, The Netherlands

Disclosures

Disclosure: Marie José Kersten, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead; Kite Pharma; Miltenyi Biotech; Novartis; Takeda
Served as a speaker or a member of a speakers bureau for: Celgene; Gilead; Kite Pharma; Novartis; Roche

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Shira Berman

Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Shira Berman has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CPD

CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapies

Authors: Jeremy Abramson, MD (moderator); Marie-José Kersten, MD, PhD; Umberto Vitolo, MD
CPD Released: 9/16/2020
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 9/16/2021, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US hematology/oncology specialists, emergency medicine physicians, and primary care physicians.

The goal of this activity is to increase knowledge about use of chimeric antigen receptor (CAR) T-cell therapy in B-cell lymphoma, including the rationale, clinical evidence and differences between available and emerging therapies, and implications for practice in selecting and monitoring treatment.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Rationale behind CAR T-cell therapy in B-cell lymphomas
- Clinical evidence for the available and emerging CAR T-cell therapies in B-cell lymphomas
Have greater confidence in
- Optimal application of available and emerging CAR T-cell therapies in B-cell lymphomas in routine practice

Disclosures

Faculty

Jeremy Abramson, MD

Associate Professor of Medicine
Harvard Medical School
Director
Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts, United States

Disclosures

Disclosure: Jeremy Abramson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Allogene; Abbvie; Bristol Myers Squibb; Celgene; EMD Serono; Karyopharm; Kite Pharma; Morphosys; Novartis; Roche
Received grants for clinical research from: Celgene; Seattle Genetics

Umberto Vitolo, MD

Hematology Consultant
Candiolo Cancer Institute
Candiolo, Italy

Disclosures

Disclosure: Umberto Vitolo, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Celgene; Gilead; Janssen; Novartis
Served as a speaker or a member of a speakers bureau for: AbbVie; Celgene; Gilead; Janssen; Roche

Marie José Kersten, MD, PhD

Professor of Hematology
Department of Hematology
LYMMCARE (Lymphoma and Melanoma Center Amsterdam) Institute
Amsterdam University Medical Centers
Amsterdam, The Netherlands

Disclosures

Disclosure: Marie José Kersten, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Gilead; Kite Pharma; Miltenyi Biotech; Novartis; Takeda
Served as a speaker or a member of a speakers bureau for: Celgene; Gilead; Kite Pharma; Novartis; Roche

Editors

Sanneke Koekkoek

Medical Education Director, WebMD Global, LLC

Disclosures

Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

Shira Berman

Scientific Content Manager, WebMD Global, LLC

Disclosures

Disclosure: Shira Berman has disclosed no relevant financial relationships.

Content Reviewer

Robert Morris, PharmD

Associate Director, Accreditation and Compliance

Disclosures

Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: ViiV Healthcare
Owns stock, stock options, or bonds from: GlaxoSmithKline

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

From Medscape Education

CPD

CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapies

Authors: Jeremy Abramson, MD (moderator); Marie-José Kersten, MD, PhD; Umberto Vitolo, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CPD Released: 9/16/2020

Valid for credit through: 9/16/2021, 11:59 PM EST

processing....

Commentaire d'expert en français

Ce commentaire fait partie d’une activité de formation plus vaste. Après la participation, prière de retourner à CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapies pour accéder à l’ensemble du contenu de formation relié.

« Return to: CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapies

Download Slides

Activity Transcript

Expert Commentary

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Jeremy Abramson, MD

Umberto Vitolo, MD

Marie José Kersten, MD, PhD

Editors

Sanneke Koekkoek

Shira Berman

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

CPD

CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapies

Target Audience and Goal Statement

Disclosures

Faculty

Jeremy Abramson, MD

Umberto Vitolo, MD

Marie José Kersten, MD, PhD

Editors

Sanneke Koekkoek

Shira Berman

Content Reviewer

Robert Morris, PharmD

Peer Reviewer

Accreditation Statements

For Physicians

Instructions for Participation and Credit

CAR T Cells in B-Cell Lymphoma: Implications of New Data and New Therapies

Commentaire d'expert en français

Expert Commentary